Guy Oliver leaves Ipsen for BMS

12 March 2024

New Zealander Guy Oliver (pictured above) has left his role as Ipsen’s (Euronext: IPN) general manager for the UK and Ireland, to take up the same position at Bristol Myers Squibb (NYSE: BMY).

He will also sit on BMS’ European markets leadership team, reporting into Monica Shaw, senior vice president and head of European markets, who called him “the perfect leader to carry out our mission of helping patients prevail over serious diseases.”

She added: “We are thrilled to welcome Guy at this pivotal moment for us as we expand our portfolio, bringing new and innovative medicines to help patients across a broadening range of chronic conditions in the UK and Ireland.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK